Disparities in immune and targeted therapy utilization for older US patients with metastatic renal cell carcinoma.
Disparities in immune and targeted therapy utilization for older US patients with metastatic renal cell carcinoma.
复制标题
DOI：
10.1093/jncics/pkad036
复制
发表时间：
2023-05-02
影响因子：
4.4
通讯作者：
中科院分区：
文献类型：
--
作者：
在口服抗癌药（OAA）和免疫治疗（IO）时代，转移性肾细胞癌（mRCC）结局的差异持续存在。我们研究了2015年至2019年美国医疗保险受益人中mRCC系统治疗使用的变化。Logistic回归模型评估了治疗接受与人口统计学协变量（包括患者种族、民族和性别）之间的相关性。共有15407例患者符合研究标准。多变量校正后，非西班牙裔黑人人种和种族与IO减少相关（调整后的相对风险比[aRRR] = 0.76，95%置信区间[CI] = 0.61至0.95; P = .015）（aRRR = 0.76，95% CI = 0.64 - 0.90; P = .002）与非西班牙裔白色人种和种族相比。与男性相比，女性与IO减少（aRRR = 0.73，95% CI = 0.66至0.81; P < .001）和OAA接受（aRRR = 0.74，95% CI = 0.68至0.81; P < .001）相关。因此，从2015年到2019年，在医疗保险受益人的mRCC系统治疗利用中观察到了种族，种族和性别的差异。
Disparities in metastatic renal cell carcinoma (mRCC) outcomes persist in the era of oral anticancer agents (OAAs) and immunotherapies (IOs). We examined variation in the utilization of mRCC systemic therapies among US Medicare beneficiaries from 2015 to 2019. Logistic regression models evaluated the association between therapy receipt and demographic covariates including patient race, ethnicity, and sex. In total, 15 407 patients met study criteria. After multivariable adjustment, non-Hispanic Black race and ethnicity was associated with reduced IO (adjusted relative risk ratio [aRRR] = 0.76, 95% confidence interval [CI] = 0.61 to 0.95; P = .015) and OAA receipt (aRRR = 0.76, 95% CI = 0.64 to 0.90; P = .002) compared with non-Hispanic White race and ethnicity. Female sex was associated with reduced IO (aRRR = 0.73, 95% CI = 0.66 to 0.81; P < .001) and OAA receipt (aRRR = 0.74, 95% CI = 0.68 to 0.81; P < .001) compared with male sex. Thus, disparities by race, ethnicity, and sex were observed in mRCC systemic therapy utilization for Medicare beneficiaries from 2015 to 2019.
登录
查看更多内容
影响因子：
23.4
作者：
Bhindi, Bimal;Thompson, R. Houston;Leibovich, Bradley C.
通讯作者：
Leibovich, Bradley C.
DOI：
10.1007/s10552-015-0594-4
发表时间：
2015-07
期刊：
Cancer causes & control : CCC
影响因子：
--
作者：
Lin J;Zahm SH;Shriver CD;Purdue M;McGlynn KA;Zhu K
通讯作者：
Zhu K
DOI：
10.3233/kca-210119
发表时间：
2021
期刊：
Kidney cancer (Clifton, Va.)
影响因子：
--
作者：
Wilson LE;Spees L;Pritchard J;Greiner MA;Scales CD Jr;Baggett CD;Kaye D;George DJ;Zhang T;Wheeler SB;Dinan MA
通讯作者：
Dinan MA
DOI：
10.1056/nejmoa1510665
发表时间：
2015-11-05
期刊：
The New England journal of medicine
影响因子：
--
作者：
Motzer RJ;Escudier B;McDermott DF;George S;Hammers HJ;Srinivas S;Tykodi SS;Sosman JA;Procopio G;Plimack ER;Castellano D;Choueiri TK;Gurney H;Donskov F;Bono P;Wagstaff J;Gauler TC;Ueda T;Tomita Y;Schutz FA;Kollmannsberger C;Larkin J;Ravaud A;Simon JS;Xu LA;Waxman IM;Sharma P;CheckMate 025 Investigators
通讯作者：
CheckMate 025 Investigators
DOI：
10.1016/j.urolonc.2014.01.002
发表时间：
2014-07
期刊：
Urologic oncology
影响因子：
--
作者：
Patel HD;Kates M;Pierorazio PM;Allaf ME
通讯作者：
Allaf ME